论文部分内容阅读
目的比较莫西沙星治疗社区获得性肺炎(CAP)有效和无效患者的临床特点,了解莫西沙星治疗CAP无效的相关因素,提高莫西沙星治疗CAP的效果。方法回顾性分析50例经莫西沙星治疗的CAP患者的资料,评价治疗后的临床疗效,比较治疗有效组和无效组的临床特征和检查结果。结果 50例CAP患者经莫西沙星治疗后有效31例(62.00%)作为有效组,无效19例(38.00%)作为无效组。治疗有效组男19例(61.29%),治疗无效组男15例(78.95%)。2组年龄、CURB-65评分、白蛋白水平、CRP值、住院时间比较差异有统计学意义(P<0.05);2组白细胞数、淋巴细胞数、中性粒细胞计数、血小板计数、LNR、BNP、超过2叶肺浸润、基础疾病、临床症状比较差异无统计学意义(P>0.05)。结论选择莫西沙星治疗CAP时需考虑患者的年龄、CURB-65评分、白蛋白水平、CRP值制定有效的的治疗策略,促进临床合理用药。
Objective To compare the clinical characteristics of moxifloxacin in the treatment of patients with community-acquired pneumonia (CAP) effective and ineffective, to understand the related factors of moxifloxacin in the treatment of CAP ineffective and to improve the efficacy of moxifloxacin in the treatment of CAP. Methods The data of 50 patients with CAP treated with moxifloxacin were retrospectively analyzed. The clinical efficacy after treatment was evaluated. The clinical features and the results of the treatment were compared. Results 50 cases of CAP patients were treated with moxifloxacin effective in 31 cases (62.00%) as the effective group, ineffective in 19 cases (38.00%) as invalid group. Treatment effective group 19 males (61.29%), treatment ineffective group of 15 males (78.95%). There was significant difference between the two groups in age, CURB-65 score, albumin level, CRP value and hospital stay (P <0.05). The number of leucocyte, lymphocyte, neutrophil, BNP, more than 2 leaves pulmonary infiltrates, basic diseases, clinical symptoms showed no significant difference (P> 0.05). Conclusion The choice of moxifloxacin in patients with CAP should take into account the patient’s age, CURB-65 score, albumin level, CRP value to develop effective treatment strategies to promote clinical rational use of drugs.